Suppr超能文献

[卵巢癌中癌症干细胞的检测]

[Detection of cancer stem cells in ovarian cancer].

作者信息

Bartáková A, Pecková K, Daum O, Bouda J

出版信息

Ceska Gynekol. 2014 Jan;79(1):7-11.

Abstract

OBJECTIVE

Detection of cancer stem cells (CSCs) in ovarian cancer, influence of CSCs on overall survival, disease free interval. Results in comparison with literature.

DESIGN

Original study.

SETTINGS

Department of Gynaecology and Obstetrics, Faculty Hospital Pilsen and Medical Faculty in Pilsen, Charles University, Šikls Institute of Pathology, Faculty Hospital Pilsen and Medical Faculty in Pilsen, Charles University.

METHODS

23 specimens of papillary-serous ovarian carcinoma and 4 specimens of endometroid ovarian carcinoma were included in the study. Specific antibodies to CD44 and CD133 antigens were used. Immunoreaction of both CD44 and CD133 was evaluated for the high power field.

RESULTS

There was no significant correlation between CD44 expression and disease free interval and overall survival. CD133 expression was not evaluated due to an inadequate immunoreaction antibody - antigene.

CONCLUSION

We did not find any statistically correlation between CD44 expression and overall survival and disease free interval in our series of patients with ovarian carcinoma. It seems to be better to use different antibody for CD133 detection.

摘要

目的

检测卵巢癌中的癌症干细胞(CSCs),CSCs对总生存期、无病生存期的影响。结果与文献比较。

设计

原创性研究。

地点

比尔森大学医院妇产科、比尔森医学院、查尔斯大学、比尔森大学医院Šikls病理研究所、比尔森医学院、查尔斯大学。

方法

本研究纳入23例乳头状浆液性卵巢癌标本和4例子宫内膜样卵巢癌标本。使用针对CD44和CD133抗原的特异性抗体。在高倍视野下评估CD44和CD133的免疫反应。

结果

CD44表达与无病生存期和总生存期之间无显著相关性。由于免疫反应抗体-抗原不足,未评估CD133表达。

结论

在我们的卵巢癌患者系列中,未发现CD44表达与总生存期和无病生存期之间存在任何统计学相关性。似乎最好使用不同的抗体来检测CD133。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验